A
Aetion
Delivering real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers
About Aetion
Aetion is a technology startup that operates in the healthcare sector, specifically in the area of real-world evidence (RWE). The company develops software solutions that help life sciences developers, regulators, and purchasers make critical decisions based on real-world data. Aetion's software provides insights into how medical innovations work in real-world settings, from initial hypothesis to long-term safety monitoring.
Read full description
The company's clients include major players in the life sciences industry, such as pharmaceutical companies and healthcare regulators. Aetion's software allows these clients to generate and analyze a wide range of data, providing clinical insights that were previously unavailable. This data-driven approach helps expedite care and treatment options for patients in need.
Aetion's business model revolves around its software platform and complementary apps, which are designed to manage longitudinal data and generate synthetic health data using artificial intelligence (AI). The company also offers data, science, and regulatory services to help shape and speed up clients' real-world data strategies.
Aetion makes money by selling its software solutions and services to its clients. The company's value proposition is the ability to maximize return on investment on real-world data, by providing quick insights and facilitating critical decisions based on this data.
In conclusion, Aetion is a healthcare technology startup that leverages real-world data to help life sciences companies make informed decisions and expedite patient care.
At a glance
- Founded
- 2012
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Aetion.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
Flare Capital Partners
Lakestar
NEA
Amgen Ventures
Oxeon
McKesson Ventures
EDBI
Sanofi
Greenspring Associates
UCB Ventures
Johnson & Johnson Innovation
Horizon Blue Cross Blue Shield of New Jersey
Series B and later4 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aetion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aetion on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.